Brief: Ascletis Pharma Sees HY Net Loss Attributable RMB127.3 Million To RMB132.3 Million
07/08/2024 16:03
Aug 7 (Reuters) - Ascletis Pharma 1672.HK :
* SEES NET LOSS ATTRIBUTABLE RMB127.3 MILLION TO RMB132.3
MILLION
FOR SIX MONTHS
* EXPECTED RESULT DUE TO CONTRACTION OF MARKET DEMAND FOR
RITONAVIR PRODUCT, OTHERS
Further company coverage: 1672.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ascletis Pharma
See all newsAscletis hits 4-week high on initiating US Phase I study on obesity drug
Brief: Ascletis Pharma Initiates U.S. Phase I Study For ASC36 Oral Tablets For Obesity
Brief: Ascletis Pharma Inc. Says Board Of Directors Does Not Recommend Payment Of Any Dividend In Respect Of HY
China's Ascletis Pharma H1 net loss widens on higher R&D costs
Brief: Ascletis Announces First Participant Dosed In A Global Phase III Clinical Program Of Once-Daily Oral Small Molecule Glp-1 Receptor Agonist ASC30 For Chronic Weight Management